Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5685757 | American Journal of Kidney Diseases | 2016 | 5 Pages |
Abstract
Pemetrexed is an approved antimetabolite agent, now widely used for treating locally advanced or metastatic nonsquamous non-small cell lung cancer. Although no electrolyte abnormalities are described in the prescribing information for this drug, several case reports have noted nephrogenic diabetes insipidus with associated acute kidney injury. We present a case of nephrogenic diabetes insipidus without severely reduced kidney function and propose a mechanism for the isolated finding. Severe hypernatremia can lead to encephalopathy and osmotic demyelination, and our report highlights the importance of careful monitoring of electrolytes and kidney function in patients with lung cancer receiving pemetrexed.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Enrica MD, MPH, Shuchi MD, MS, Vivek MD,